Here are the 10-K annual reports from ProtoKinetix Inc (PKTX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow PKTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PKTX filings page.
ProtoKinetix, Inc. (PKTX) filed its annual report as a development-stage biotechnology company focused on anti-freeze glycoproteins (AAGP®) for cell, tissue and organ preservation and other medical uses. The company remains pre-revenue and is concentrating on research collaborations and commercial validation of its AAGP® technology.
For the year ended December 31, 2025, ProtoKinetix reported a net loss of $393,650, slightly higher than the $364,188 loss in 2024, driven mainly by $177,610 in professional fees and $106,613 in research and development expenses. Cash at year-end was only $1,118, with a working capital deficiency of $183,266 and an accumulated deficit of $48.6 million, and the auditor and management both state that these conditions raise substantial doubt about the company’s ability to continue as a going concern.
During 2025, the company raised $197,500 through common stock sales, issued shares for consulting services and to settle debt, and capitalized $56,308 of patent-related intangible assets, bringing intangible assets to $481,206. Management discloses material weaknesses in internal control over financial reporting, including insufficient segregation of duties and limited formal corporate governance documentation. As of December 31, 2025, 406,830,152 common shares were outstanding, increasing to 411,630,152 shares by September 3, 2026.